Sanofi on Thursday mentioned it is planning to chop the U.S. worth of its hottest insulin drug by 78% and cap month-to-month out-of-pocket prices at $35 for individuals who have personal insurance coverage beginning subsequent 12 months. 

The French drugmaker is the final main insulin producer to attempt to head off authorities efforts to cap month-to-month prices by saying its personal steep worth cuts for the lifesaving hormone. 

Eli Lilly and Novo Nordisk made comparable sweeping cuts earlier this month after years of political stress and public outrage. The three corporations management over 90% of the worldwide insulin market. 

“Sanofi believes that nobody ought to wrestle to pay for his or her insulin and we’re happy with our continued actions to enhance entry and affordability for tens of millions of sufferers for a few years,” mentioned Olivier Bogillot, Sanofi’s U.S. head of common medicines. The change takes impact Jan. 1.

Roughly 37 million folks within the U.S., or 11.3% of the nation’s inhabitants, have diabetes, based on the Facilities for Illness Management and Prevention.